Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

News and Events

engineered natural killer cells (yellow) can expand in solid tumors and kill tumor cells (red)

Stem cell–derived natural killer cells engineered to attack solid tumors

Cancer-killing natural killer cells could pave the way to off-the-shelf immunotherapy for solid tumors.

Cartoon doctor and patient discussing lung scan

Clinical trial researches antibiotic therapy for lung cancer

A clinical trial led by Chen Zhao, M.D., Stadtman Investigator in the Thoracic and GI Malignancies Branch, is researching a combination therapy for non-small cell lung cancer.

New findings highlight shared features of human and canine osteosarcoma

Molecular signatures of canine osteosarcoma prognosis could also predict clinical outcomes for human osteosarcomas.

Clinical trial researching immunotherapy for lung cancer

David S. Schrump, M.D., M.B.A., FACS, Chief of the Thoracic Surgery Branch, is leading a trial researching immunotherapy for non-small cell lung cancer.

Asian doctor with African American patient

Clinical trial researching therapy for recurrent respiratory papillomatosis

Scott M. Norberg, D.O., Assistant Research Physician in the Center for Immuno-Oncology, is leading a trial researching drug therapy to reduce necessary surgeries for recurrent respiratory papillomatosis.

Shining a light on an elusive cancer metabolite

Researchers have long sought a means for subcellular imaging of acetyl-CoA, a metabolite suspected to play a critical role in turning genes on and off. In an important advance, CCR researchers have invented a glowing biosensor to detect the elusive metabolite, paving the way for future studies.

Seldom-studied immune cells in the liver may be helpful in treating cancer

CCR researchers have discovered that certain immune cells in the liver, called MAITs, often surround liver tumors but fail to infiltrate them. An analysis suggests that treatment with immune checkpoint inhibitors could potentially trigger these immune cells to help them infiltrate and attack the tumors.

Clinical trial researches bone marrow transplants for blood cancers

A clinical trial led by Christopher G. Kanakry, M.D., Lasker Clinical Research Scholar in the Center for Immuno-Oncology, is researching bone marrow transplants for some types of blood cancers, such as high-risk leukemia, lymphoma, myelodysplastic syndrome or multiple myeloma.

CCR Hosts Communications Course for Healthcare Providers in Oncology

Dedicated transdisciplinary teams of healthcare providers from the CCR’s Clinical Care Programs gathered to learn communication skills centered on essential topics of patient care.

A stain of HPV-negative head and neck squamous cell carcinoma that has high levels of SMYD3

Chromatin modifier linked to immunotherapy resistance in HPV-negative head and neck cancers

Researchers have discovered that a chromatin-regulating enzyme called SMYD3 limits the access of cancer-attacking immune cells to HPV-negative head and neck cancers, therefore decreasing immunotherapy’s effectiveness. Depleting SMYD3 increased the cancer’s sensitivity to a standard immunotherapy drug in mouse models.

New insights explain how the same protein can serve different functions

Proteins can often choose between potential interacting partners and serve different functions inside cells. How these choices are made is not entirely clear. New research shows that the exact location in a cell where the protein is produced and the rate of its synthesis are key factors in this choice.

Breadcrumb

News and Events